1
|
王 可, 李 娟, 孙 建, 李 力, 张 西, 张 建, 余 敏, 叶 贤, 张 明, 张 瑜, 姚 文, 黄 媚. [Recommendations from Experts in the Management of Adverse Reactions
to ALK Inhibitors (2021 Version)]. Zhongguo Fei Ai Za Zhi 2021; 24:815-828. [PMID: 34670356 PMCID: PMC8695243 DOI: 10.3779/j.issn.1009-3419.2021.102.32] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Anaplastic lymphoma kinase (ALK) fusion gene, as a tumor driver gene, was crucial for the occurrence and development of non-small cell lung cancer (NSCLC). Recently, targeted ALK fusion gene has become the main treatment method for ALK-positive NSCLC. The first and second generation ALK inhibitors (ALKi), such as crizotinib, ceritinib, alectinib and ensartinib have been approved in China. However, there was no guidance for the management of ALKi adverse reactions. Therefore, this "Recommendations from experts in the management of adverse reactions to ALK inhibitors (2021 version)" has been summarized, led by Lung Cancer Professional Committee of Sichuan Cancer Society and Sichuan Medical Quality Control Center for Tumor Diseases, to provide practical and feasible strategies for clinical ALKi management specification of adverse reactions.
.
Collapse
Affiliation(s)
- 可 王
- 610041 成都,四川大学华西医院呼吸与危重症医学科Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China
| | - 娟 李
- 610041 成都,四川省肿瘤医院肿瘤内科Department of Oncology, Sichuan Cancer Hospital, Chengdu 610041, China
| | - 建国 孙
- 400037 重庆,陆军军医大学新桥医院肿瘤科Department of Oncology, Xinqiao Hospital, Army Military Medical University, Chongqing 400037, China
| | - 力 李
- 400042 重庆,陆军特色医学中心(大坪医院)呼吸与危重症医学科Department of Respiratory and Critical Care Medicine, Army Special Medical Center (Daping Hospital), Chongqing 400042, China
| | - 西 张
- 610000 成都,成都市第三人民医院肿瘤科Department of Oncology, Chengdu Third People's Hospital, Chengdu 610000, China
| | - 建勇 张
- 563000 遵义,呼吸与危重症医学科,遵义医科大学附属医院Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China
| | - 敏 余
- 610041 成都,四川大学华西医院胸部肿瘤科Department of Thoracic Oncology, West China Hospital of Sichuan University, Chengdu 610041, China
| | - 贤伟 叶
- 550002 贵阳,贵州省人民医院呼吸与危重症医学科Department of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - 明 张
- 650118 昆明,云南省肿瘤医院放射治疗科Department of Radiation Therapy, Yunnan Cancer Hospital, Kunming 650118, China
| | - 瑜 张
- 550002 贵阳,贵州省人民医院肿瘤科Department of Oncology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - 文秀 姚
- 610041 成都,四川省肿瘤医院肿瘤内科Department of Oncology, Sichuan Cancer Hospital, Chengdu 610041, China
| | - 媚娟 黄
- 610041 成都,四川大学华西医院胸部肿瘤科Department of Thoracic Oncology, West China Hospital of Sichuan University, Chengdu 610041, China
| |
Collapse
|